Evidence map›Paper›PMID 37215123›Full record

ArticleFrontiers in immunology2023

Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals.

Joana Barros-Martins, Swantje I Hammerschmidt, Gema Morillas Ramos, Anne Cossmann, Laura Hetzel, Ivan Odak, Miriam Köhler, Metodi V Stankov, Christiane Ritter, Michaela Friedrichsen and 10 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Joana Barros-MartinsInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Swantje I HammerschmidtInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Gema Morillas RamosDepartment for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Anne CossmannDepartment for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Laura HetzelDepartment for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Ivan OdakInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Miriam KöhlerInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Metodi V StankovDepartment for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Christiane RitterInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Michaela FriedrichsenInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Inga RavensInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Anja SchimrockInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Jasmin RistenpartInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Anika JanssenInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Stefanie WillenzonInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Günter BernhardtInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Ralf LichtinghagenDepartment of Clinical Chemistry, Hannover Medical School, Hannover, Germany.
Berislav BošnjakInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Georg M N BehrensDepartment for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Reinhold FörsterInstitute of Immunology, Hannover Medical School, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since early 2022, various Omicron variants have dominated the SARS-CoV-2 pandemic in most countries. All Omicron variants are B-cell immune escape variants, and antibodies induced by first-generation COVID-19 vaccines or by infection with earlier SARS-CoV-2 variants largely fail to protect individuals from Omicron infection. In the present study, we investigated the effect of Omicron infections in triple-vaccinated and in antigen-naive individuals. We show that Omicron breakthrough infections occurring 2-3.5 months after the third vaccination restore B-cell and T-cell immune responses to levels similar to or higher than those measured 14 days after the third vaccination, including the induction of Omicron-neutralizing antibodies. Antibody responses in breakthrough infection derived mostly from cross-reacting B cells, initially induced by vaccination, whereas Omicron infections in antigen-naive individuals primarily generated B cells binding to the Omicron but not the Wuhan spike protein. Although antigen-naive individuals mounted considerable T-cell responses after infection, B-cell responses were low, and neutralizing antibodies were frequently below the limit of detection. In summary, the detection of Omicron-associated B-cell responses in primed and in antigen-naive individuals supports the application of Omicron-adapted COVID-19 vaccines, but calls into question their suitability if they also contain/encode antigens of the original Wuhan virus.

Indexed as

COVID-19Antibodies, NeutralizingBreakthrough InfectionsCOVID-19 VaccinesHumansSARS-CoV-2Antibodies, NeutralizingCOVID-19 Vaccinesbreakthrough infectionCOVID-19heterologous vaccinationOmicron infectionOmicron variantsSARS-CoV-2

Identifiers

PMID37215123
PMCPMC10196199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.